- Home
- KNOP vs ACRV Comparison
KNOP vs ACRV Comparison
Compare KNOP & ACRV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KNOP
- ACRV
- Stock Information
- Founded
- KNOP 2013
- ACRV 2018
- Country
- KNOP United Kingdom
- ACRV United States
- Employees
- KNOP N/A
- ACRV N/A
- Industry
- KNOP Marine Transportation
- ACRV Medicinal Chemicals and Botanical Products
- Sector
- KNOP Consumer Discretionary
- ACRV Health Care
- Exchange
- KNOP Nasdaq
- ACRV Nasdaq
- Market Cap
- KNOP 235.1M
- ACRV 247.8M
- IPO Year
- KNOP 2013
- ACRV 2022
- Fundamental
- Price
- KNOP $6.07
- ACRV $6.96
- Analyst Decision
- KNOP
- ACRV Strong Buy
- Analyst Count
- KNOP 0
- ACRV 5
- Target Price
- KNOP N/A
- ACRV $22.40
- AVG Volume (30 Days)
- KNOP 58.4K
- ACRV 47.9K
- Earning Date
- KNOP 12-04-2024
- ACRV 11-13-2024
- Dividend Yield
- KNOP 1.71%
- ACRV N/A
- EPS Growth
- KNOP N/A
- ACRV N/A
- EPS
- KNOP N/A
- ACRV N/A
- Revenue
- KNOP $296,181,000.00
- ACRV N/A
- Revenue This Year
- KNOP $6.70
- ACRV N/A
- Revenue Next Year
- KNOP $2.79
- ACRV N/A
- P/E Ratio
- KNOP N/A
- ACRV N/A
- Revenue Growth
- KNOP 5.27
- ACRV N/A
- 52 Week Low
- KNOP $4.94
- ACRV $3.19
- 52 Week High
- KNOP $9.11
- ACRV $11.90
- Technical
- Relative Strength Index (RSI)
- KNOP 43.92
- ACRV 34.20
- Support Level
- KNOP $5.90
- ACRV $7.69
- Resistance Level
- KNOP $6.24
- ACRV $8.54
- Average True Range (ATR)
- KNOP 0.19
- ACRV 0.44
- MACD
- KNOP 0.03
- ACRV -0.10
- Stochastic Oscillator
- KNOP 55.26
- ACRV 3.78
About KNOP KNOT Offshore Partners LP Common Units representing Limited Partner Interests
KNOT Offshore Partners LP owns, operates, and shuttles tankers under long-term charters in the North Sea and Brazil. The company provides crude oil loading, transportation, and storage services under time charters and bareboat charters. The Partnership is formed for acquiring ownership interests in over four shuttle tankers owned by Knutsen NYK Offshore Tankers AS (KNOT). It operates through the shuttle tanker market segment.
About ACRV Acrivon Therapeutics Inc.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.